Internal Reference Number: FOI_7622
Date Request Received: 18/12/2023 00:00:00
Date Request Replied To: 19/01/2024 00:00:00
This response was sent via: By Email
Request Summary: Treatment of dermatological conditions
Request Category: Companies
| Question Number 1: How many patients were treated in the last 4 months (August to November 2023) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib | |
| Answer To Question 1: • Abrocitinib - 0 • Acitretin - 30 • Alitretinoin - <5 • Azathioprine - <5 • Baricitinib - <5 • Ciclosporin - 11 • Dupilumab - 22 • Methotrexate - 33 • Mycophenolate mofetil - 0 • Pimecrolimus - 0 • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only - 7 • Tacrolimus ointment - 23 • Tralokinumab - 0 • Upadacitinib - 6 | |
| Question Number 2: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: All patients in Q1 were aged 18+ except <5 were aged 6-11 for Tacrolimus ointment treatment; <5 were aged 6-11 for Phototherapy (UVB or PUVA) for Atopic Dermatitis only; and <5 were aged 12-17 for Phototherapy (UVB or PUVA) for Atopic Dermatitis only. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
